Reviewed by Michael Gill, B. Sc.
12 Dermatomyositis Clinical Trials Near Me
Top Hospitals for Dermatomyositis Clinical Trials
Image of Washington University School of Medicine in Missouri.
Washington University School of Medicine
Saint Louis
3Active Trials
4All Time Trials for Dermatomyositis
2017First Dermatomyositis Trial
Image of Clinical Trial Site in New York.
Clinical Trial Site
New York
2Active Trials
2All Time Trials for Dermatomyositis
2021First Dermatomyositis Trial
Dermatomyositis Clinical Trials by Phase of Trial
Phase < 1 Dermatomyositis Clinical Trials
1Active Dermatomyositis Clinical Trials
1Number of Unique Treatments
1Number of Active Locations
Dermatomyositis Clinical Trials by Age Group
Most Recent Dermatomyositis Clinical Trials
Top Treatments for Dermatomyositis Clinical Trials
Treatment Name
Active Dermatomyositis Clinical Trials
All Time Trials for Dermatomyositis
First Recorded Dermatomyositis Trial
Brepocitinib
1
1
2022
Baricitinib
1
3
2022
Anti-Beta Interferon (PF-06823859)
1
1
2021
IS (MMF or MPA)
1
1
2021
Ravulizumab
1
1
2021
Recently Completed Studies with FDA Approved Treatments for Dermatomyositis
Treatment
Year
Sponsor
Lenabasum 20 mg
2018
Corbus Pharmaceuticals Inc.

What Are Dermatomyositis Clinical Trials?

Dermatomyositis is one of the rare and inflammatory myopathy diseases characterized by skin rashes and chronic muscle weakness. Some of the symptoms of Dermatomyositis are:

  • Purple or red rash on the eyelids and skin exposed to the sun
  • Deposits of calcium under the skin
  • Weakness of neck, back, hip, and shoulder muscles
  • Tiredness, weight loss, and fever
  • Difficulty in swallowing and talking

Dermatomyositis can occur in people of all ages. Hence, Dermatomyositis clinical trials are performed to identify how the condition affects adults and children and treatments that offer the best results.

Why Is Dermatomyositis Being Studied Through Clinical Trials?

Statistics show that Dermatomyositis can occur from infancy to 80 years. However, most cases occur between the ages of 40 and 60. Dermatomyositis prevalence is 9.63 cases/million. In children, symptoms of Dermatomyositis occur between 5 and 15. And nearly 3/1000,000 children are found affected with juvenile Dermatomyositis. Similarly, females are twice as more affected by Dermatomyositis than males.

The root cause of Dermatomyositis is still unknown. However, possible causes may include abnormal genes, autoimmune diseases, and medication.

Since it is a rare condition and the cause is unknown, researchers continue to perform Dermatomyositis clinical trials. Moreover, Dermatomyositis is also being studied through clinical trials because the disease can lead to life-threatening complications like heart and lung disease.  

What Are the Types of Treatments Available for Dermatomyositis?

Though no cure is available so far for Dermatomyositis, there are treatments to manage the condition and symptoms. These include:

  • Physical therapy and orthotics devices are used to strengthen muscles
  • Anti-inflammatory steroid help ease body inflammation  
  • Immunoglobulin drugs are given to boost immunity. They are infused directly into the bloodstream through a drip.
  • Surgery may also be recommended in patients to remove calcinosis (calcium deposits) under the skin if infected or painful.

What Are Some Recent Breakthrough Clinical Trials for Dermatomyositis?

2007: A Pilot Trial of Rituximab in the Treatment of Patients with Dermatomyositis-This study was conducted to evaluate the efficacy of Rituximab therapy on patients suffering from Dermatomyositis. The patients were given two Rituximab infusions two weeks apart. The research concluded modest effects of depletion of peripheral B cells on muscle disease. These infusions were tolerated well by patients with no complications caused by severe infection.

2022: Safety and Efficacy of Lenabasum- A randomized clinical trial was conducted to evaluate Lenabasum efficacy for Dermatomyositis. The participants were daily given 20mg of Lenabasum for 28 days. Then they were given 20 mg twice daily for 56 days. The treatment was well-tolerated in patients with significant improvement in Cutaneous Dermatomyositis disease.  

Who Are Some of the Key Opinion Leaders / Researchers / Institutions Conducting Dermatomyositis Clinical Trial Research?

Myositis Support and Understanding Association (MSU) is a non-profit organization that empowers people with Dermatomyositis through support, research, education, advocacy, and financial assistance.

Muscular Dystrophy Association (MDA)  is committed to transforming people's lives with muscular and neuromuscular diseases via care, advocacy, and research.

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 5th, 2021

Last Reviewed: October 3rd, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

References1 Vaziri H, Turshudzhyan A, Vecchio E. Immunotherapy-induced Colitis: A Comprehensive Review of Epidemiology, Clinical Presentation, Diagnostic Workup, and Management Plan. J Clin Gastroenterol. 2022 Apr 21. doi: 10.1097/MCG.0000000000001705. [Epub ahead of print] https://pubmed.ncbi.nlm.nih.gov/354703012 Vaziri H, Turshudzhyan A, Vecchio E. Immunotherapy-induced Colitis: A Comprehensive Review of Epidemiology, Clinical Presentation, Diagnostic Workup, and Management Plan. J Clin Gastroenterol. 2022 Aug 1;56(7):555-564. doi: 10.1097/MCG.0000000000001705. Epub 2022 Apr 21. https://pubmed.ncbi.nlm.nih.gov/354703013 Vaziri H, Turshudzhyan A, Vecchio E. Immunotherapy-induced Colitis: A Comprehensive Review of Epidemiology, Clinical Presentation, Diagnostic Workup, and Management Plan. J Clin Gastroenterol. 2022 Aug 1;56(7):555-564. doi: 10.1097/MCG.0000000000001705. Epub 2022 Apr 21. Review. https://pubmed.ncbi.nlm.nih.gov/35470301